Register entry

McLaughlin Gormley King Company

Data as of · How to read this entry

Registered sites
1
Active NDC listings
2
Live patents
0
Countries
1
Base
United States
Authorisation

Registered operations

Analytical testing1Active ingredient (API) manufacture1Labelling1
Sites

Registered establishments

1
EstablishmentAddressRegistered forFEI / DUNS
McLaughlin Gormley King Company4001 PEAVEY RD, CHASKA, Minnesota (MN) 55318, United States (USA)Analytical testing, Active ingredient (API) manufacture, Labelling2110594836075978
Catalogue

Drug listings by form and route

2

2 active NDC listings: 2 drug for further processing. By marketing category: DRUG FOR FURTHER PROCESSING 2.

Dosage formNDCs
liquid2
RouteNDCs
Labeller name on the listingNDCs
mclaughlin gormley king company2
Catalogue

Marketed products

2
BrandGeneric nameForm / routeNDC
-Pyrethrum Extractliquid55464-100DRUG FOR FURTHER PROCESSING
-Pyrethrum Extract and Piperonyl Butoxideliquid55464-101DRUG FOR FURTHER PROCESSING
Neighbours

Registered in the same town

1
Compare

Comparable companies in United States

Enquiry

Common questions

Is McLaughlin Gormley King Company FDA approved?
McLaughlin Gormley King Company holds 1 FDA-registered establishment in the United States. Registration puts a site on the FDA's register and open to inspection; it is not an approval of the company. Approvals attach to individual drug applications.
Where are McLaughlin Gormley King Company's drugs manufactured?
The FDA register lists CHASKA, MN. Registered operations: analytical testing, active ingredient (API) manufacture, labelling.
What drugs does McLaughlin Gormley King Company make?
2 products are listed under McLaughlin Gormley King Company in the openFDA NDC Directory, most often as liquid. The full breakdown by dosage form and route is above. A listing count is not a sales figure.

Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.